New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:36 EDTIDRAIdera announces expansion of pipeline into two orphan autoimmune diseases
Idera Pharmaceuticals announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The company plans to submit a protocol to the U.S. Food and Drug Administration in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
09:27 EDTIDRAIdera Pharmaceuticals Chief Medical Officer resigns
Idera Pharmaceuticals disclosed in a regulatory filing that Louis Brenner, M.D. resigned his positions as senior VP and Chief Medical Officer of Idera to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use